Telomir Pharmaceuticals (NASDAQ: TELO) announced the publication of peer-reviewed preclinical data in Advances in Redox Research demonstrating that its lead compound, Telomir-Zn, delivered dose-dependent survival improvements and multiple therapeutic benefits in a Wilson’s disease model. The study showed reduced oxidative stress, lower hepatic copper burden, and improved liver function markers, supporting the biological activity of Telomir-Zn in Wilson’s disease. This research expands the company’s scientific validation as it advances its lead triple-negative breast cancer program toward Phase 1/2 clinical initiation.
Wilson’s disease is a genetic disorder characterized by excessive copper accumulation in the liver, brain, and other organs, leading to severe hepatic and neurological symptoms. Current treatments include chelation therapy and zinc acetate, which can be associated with side effects and limited efficacy. The preclinical findings suggest that Telomir-Zn may offer a novel approach by modulating intracellular metal homeostasis and redox balance. In the study, Telomir-Zn treatment resulted in significant reductions in hepatic copper content and markers of oxidative stress, alongside improvements in liver enzymes, indicating potential for disease modification.
Telomir Pharmaceuticals, a preclinical-stage biotechnology company, focuses on developing small-molecule therapeutics targeting fundamental epigenetic and metabolic mechanisms implicated in cancer, aging, and degenerative disease. Telomir-Zn has shown activity in preclinical studies involving modulation of intracellular metal homeostasis, redox balance, epigenetically regulated gene expression, mitochondrial function, and genomic stability. The company’s lead program is Telomir-1 (Telomir-Zn), which is being evaluated for multiple indications.
The publication in Advances in Redox Research adds to the growing body of evidence supporting Telomir-Zn’s therapeutic potential. According to the company, the findings underscore the compound’s ability to address key pathological features of Wilson’s disease, including copper overload and oxidative stress. The data also align with the company’s broader strategy to develop therapies that target fundamental disease mechanisms.
For more information, the full press release is available at https://ibn.fm/fOSNo. The latest news and updates relating to TELO can be found in the company’s newsroom at https://ibn.fm/TELO.
